Healthcare sector | Medical Devices industry
| Price | $0.96 |
|---|---|
| Shares Outstanding | 10.53M |
| All-Time Low | $0.67 |
| 52-Week Low | $0.67 |
| Net Cash / Share | $0 |
|---|---|
| Net Current Assets / Share | $-0.28 |
| Net Tangible Assets / Share | $0.69 |
| Shares Outstanding Ave Change (Annual) | 40.35% |
| Shares Δ YoY | 79.89% |
| Avg CA Burn (Annual %) | -41.89% (as of 2-23-2026) |
| Avg CA Burn (Quarterly %) | 9.48% (as of 2-23-2026) |
| Max Earning Power / Share | $-5.11 |
|---|---|
| Adjusted Earning Power |
$-6.64
adjustedEarningPower = (Net Income / EP_MULTIPLIER) / Shares Outstanding
|
| Non-Cash Charges to Market Cap |
8.39%
nonCashChargeToMKTCAP = Non-Cash Charges / Market Capitalization
|
| Avg EBITDA (5Y) | 0 (as of 2-23-2026) |
| Avg EBITDA (5Q) | 0 (as of 2-23-2026) |
| Avg Net Income (5Y) | -51.5M (as of 2-23-2026) |
| Avg Net Income (5Q) | -8.8M (as of 2-23-2026) |
| Dividend indicators | Value | Date |
|---|---|---|
| Current Dividend Streak | No | 2-23-2026 |
| Consecutive Years Paid | No | 2-23-2026 |
| Pays Dividend | No | 2-23-2026 |
| Last Dividend Date | 1-9-17 | |
| Income indicators | Value | Date |
|---|---|---|
| EBITDA Positive | No | 2-23-2026 |
| Net Income Positive | No | 2-23-2026 |
| Current Dividend Streak | No | 2-23-2026 |
Pick a metric to view its history table and chart.
Formula: Tangible Book Value / shares from balance statements. Includes 6 quarterly + 4 annual.
Chart plots one TBV / Share point per report date (duplicate same-date annual/quarterly rows are merged).
| Report Date | Period | TBV / Share | Tangible Book Value | Shares Used |
|---|---|---|---|---|
| 2025-12-31 | Quarterly | $0.84 | 7M ($7,042,000) | 8.4M (8,404,354) |
| 2025-09-30 | Quarterly | $1.45 | 11.6M ($11,613,000) | 8M (8,009,488) |
| 2025-06-30 | Quarterly | $1.87 | 8.8M ($8,756,000) | 4.7M (4,693,284) |
| 2025-03-31 | Quarterly | $2.99 | 12.4M ($12,361,000) | 4.1M (4,128,536) |
| 2025-03-31 | Annual | $2.99 | 12.4M ($12,361,000) | 4.1M (4,128,536) |
| 2024-12-31 | Quarterly | $4.40 | 16.4M ($16,369,000) | 3.7M (3,716,432) |
| 2024-09-30 | Quarterly | $7.43 | 26.8M ($26,802,000) | 3.6M (3,609,381) |
| 2024-03-31 | Annual | $10.29 | 23.6M ($23,621,000) | 2.3M (2,295,041) |
| 2023-03-31 | Annual | $23.61 | 36.3M ($36,283,000) | 1.5M (1,536,929) |
| 2022-03-31 | Annual | $47.46 | 70.9M ($70,867,000) | 1.5M (1,493,308) |
Revenue from income statements. Includes 4 annual.
Chart plots one annual Revenue point per report date.
| Report Date | Revenue |
|---|---|
| 2025-03-31 | 3.7M ($3,705,000) |
| 2024-03-31 | 1.2M ($1,159,000) |
| 2023-03-31 | 0 ($0) |
| 2022-03-31 | 0 ($0) |
Historical cash dividends per share from Yahoo ex-dividend dates.
| Date | Dividend / Share |
|---|---|
| No dividend payment history available yet | |
| Date | Shares Outstanding | Delta |
|---|---|---|
| 2026-02-04 | 10,529,344 | +1,994,866 |
| 2026-01-22 | 8,534,478 | +524,990 |
Latest short-interest change: 737,269 shares (7.33% of float) | Days to cover: 0.04
| Date | Short Interest | Delta | Δ % |
|---|---|---|---|
| 2026-02-27 | 737,269 shares | +206,239 | +38.84% |
| 2026-02-11 | 531,030 shares | -1,904,527 | -78.20% |
Volume/ratio use shares outstanding as of the event date (frozen).
| Date | Volume | Shares Outstanding | Volume / Shares | Price |
|---|---|---|---|---|
| 2026-01-20 | 4,283,039 | 8,009,488 | 53.47% | $1.95 |
| 2026-01-16 | 6,353,273 | 8,009,488 | 79.32% | $1.70 |
| 2026-01-15 | 4,354,493 | 8,009,488 | 54.37% | $1.72 |
| 2026-01-14 | 20,030,145 | 8,009,488 | 250.08% | $1.88 |
| 2026-01-13 | 405,498,282 | 8,009,488 | 5062.72% | $2.19 |
Beyond Air, Inc., a commercial-stage medical device and biopharmaceutical company, develops the Lungfit platform, a nitric oxide (NO) generator and delivery system platform. It operates through three segments: Beyond Air, Beyond Cancer, and NeuroNos. The company offers Lungfit PH for the treatment of persistent pulmonary hypertension of the newborn. It is also developing LungFit PRO for the treatment of viral lung infections, such as community-acquired pneumonia, including COVID-19 and bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteria (NTM) at home. In addition, the company develops ultra-high concentration (UNO) that is in Phase 1 clinical trial to treat multiple solid and cutaneous tumors; and selective neuronal nitric oxide synthase (nNOS) inhibitor for the treatment of neurological conditions and autism spectrum disorder. It has a collaboration with the Yissum Research Development Company of the Hebrew University of Jerusalem, LTD to acquire the commercial rights for neuronal nitric oxide synthase inhibitors to treat autism spectrum disorder and other neurological conditions. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. Beyond Air, Inc. was founded in 2011 and is headquartered in Garden City, New York.